Company logo

ANIP - ANI Pharmaceuticals, Inc.

NASDAQ -> Healthcare -> Drug Manufacturers—Specialty & Generic
Baudette, United States
Type: Equity

ANIP price evolution
ANIP
(in millions $) 31 Dec 2023 30 Oct 2023 30 Jun 2023 31 Mar 2023
Current assets
Cash $221.12 $193.08 $161.71 $67.76
Short term investments
Net receivables $162.08 $178.84 $172.93 $174.71
Inventory $111.2 $106.59 $104.32 $103.65
Total current assets $519.82 $497.22 $459.31 $364.75
Long term investments
Property, plant & equipment $44.59 $44.19 $44.37 $43.27
Goodwill & intangible assets $237.23 $248.05 $258.52 $267.01
Total noncurrent assets $384.61 $392.69 $400.03 $400.47
Total investments
Total assets $904.42 $889.91 $859.34 $765.22
Current liabilities
Accounts payable $36.68 $34.08 $28.5 $32.69
Deferred revenue
Short long term debt $0.85 $0.85 $0.85 $0.85
Total current liabilities $145.48 $134.35 $122.86 $125.83
Long term debt $284.82 $285.03 $285.24 $285.46
Total noncurrent liabilities $301.35 $300.85 $302 $299.92
Total debt $285.67 $285.88 $286.09 $286.31
Total liabilities $446.82 $435.2 $424.87 $425.74
Shareholders' equity
Retained earnings -$80.13 -$80.88 -$90.41 -$96.25
Other shareholder equity $8.86 $14.08 $13.73 $11.13
Total shareholder equity $432.75 $429.86 $409.62 $314.63
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $221.12 $53.23 $105.3 $12.87
Short term investments
Net receivables $162.08 $169.26 $128.53 $95.79
Inventory $111.2 $105.36 $81.69 $60.8
Total current assets $519.82 $344.26 $321.77 $170.32
Long term investments
Property, plant & equipment $44.59 $43.25 $52.67 $41.27
Goodwill & intangible assets $237.23 $279.86 $322.01 $192.09
Total noncurrent assets $384.61 $415.83 $449.82 $290.87
Total investments
Total assets $904.42 $760.09 $771.6 $461.19
Current liabilities
Accounts payable $36.68 $29.3 $22.97 $11.26
Deferred revenue $0.09 $0.08
Short long term debt $0.85 $0.85 $0.85 $13.24
Total current liabilities $145.48 $99.44 $87.54 $78.56
Long term debt $284.82 $285.67 $286.52 $172.44
Total noncurrent liabilities $301.35 $322.11 $325.32 $186.93
Total debt $285.67 $286.52 $287.37 $185.69
Total liabilities $446.82 $421.55 $412.86 $265.49
Shareholders' equity
Retained earnings -$80.13 -$97.29 -$47.77 -$4.97
Other shareholder equity $8.86 $12.17 -$3.06 -$11.44
Total shareholder equity $432.75 $313.69 $333.89 $195.7
(in millions $) 31 Dec 2023 30 Oct 2023 30 Jun 2023 31 Mar 2023
Revenue
Total revenue $131.65 $116.55 $106.79
Cost of revenue $53.42 $42.28 $37.71
Gross Profit $78.23 $74.26 $69.08
Operating activities
Research & development $9.87 $7.37 $5.92
Selling, general & administrative $44.46 $38.76 $36.47
Total operating expenses $69.56 $60.88 $58.26
Operating income $8.68 $13.38 $10.82
Income from continuing operations
EBIT $6.69 $12.35 $9.86
Income tax expense -$0.21 -$1 $0.73
Interest expense $5.75 $7.1 $7.7
Net income
Net income $1.16 $6.25 $1.44
Income (for common shares) $0.75 $5.84 $1.03
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $486.82 $316.38 $216.14 $208.47
Cost of revenue $181.51 $138.78 $100.61 $87.16
Gross Profit $305.3 $177.6 $115.53 $121.32
Operating activities
Research & development $34.29 $22.32 $11.37 $16
Selling, general & administrative $161.7 $124.04 $84.29 $64.99
Total operating expenses $257.06 $208.46 $159.16 $137.83
Operating income $48.24 -$30.86 -$43.64 -$16.51
Income from continuing operations
EBIT $46.81 -$34.61 -$44.14 -$16.51
Income tax expense $1.09 -$14.77 -$13.46 -$3.41
Interest expense $26.94 $28.05 $11.92 $9.45
Net income
Net income $18.78 -$47.9 -$42.6 -$22.55
Income (for common shares) $17.15 -$49.52 -$42.79 -$22.55
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Net income $1.16 $9.94 $6.25 $1.44
Operating activities
Depreciation $15.57 $16.03 $14.75 $14.7
Business acquisitions & disposals -$2.5 -$2.81 -$4.33 -$0
Stock-based compensation $5.62 $5.44 $5.25 $4.34
Total cash flows from operations $44.74 $32.17 $20.63 $21.42
Investing activities
Capital expenditures -$2.28 -$1.74 -$2.5 -$2.35
Investments
Total cash flows from investing -$4.78 -$4.55 -$6.83 -$2.35
Financing activities
Dividends paid
Sale and purchase of stock $1.74 $4.91 $81.31 -$3.39
Net borrowings -$0.75 -$0.75 -$0.75 -$0.75
Total cash flows from financing -$11.92 $3.75 $80.15 -$4.55
Effect of exchange rate
Change in cash and equivalents $28.04 $31.37 $93.95 $14.52
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income $18.78 -$47.9 -$42.6 -$22.55
Operating activities
Depreciation $61.06 $59.65 $47.25 $44.64
Business acquisitions & disposals -$9.64 -$7.61 -$105.58 -$62.19
Stock-based compensation $20.65 $14.6 $10.49 $12.94
Total cash flows from operations $118.96 -$31.2 $3.32 $15.27
Investing activities
Capital expenditures -$8.87 -$8.13 $0.09 -$6.13
Investments
Total cash flows from investing -$18.51 -$15.74 -$105.48 -$68.32
Financing activities
Dividends paid
Sale and purchase of stock $84.56 -$0.5 $76.18 -$0.91
Net borrowings -$3 -$3 $99.02 -$0.53
Total cash flows from financing $67.44 -$5.13 $194.59 -$1.44
Effect of exchange rate
Change in cash and equivalents $167.89 -$52.07 $92.43 -$54.49
Fundamentals
Market cap $1.43B
Enterprise value $1.49B
Shares outstanding 20.48M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q 39.71%
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio 3.37
Book/Share 20.70
Cash/Share 10.80
EPS N/A
ROA N/A
ROE N/A
Debt/Equity 1.03
Net debt/EBITDA N/A
Current ratio 3.57
Quick ratio 2.81